High-tech cancer diagnostics are currently a luxury of the wealthiest health systems, but a shift in how we analyze basic tissue slides could soon level the playing field.
A new algorithm can spot hyperacute stroke tissue changes on cheap, standard CT scans, but it struggles to map the exact boundaries of smaller lesions.
Clinical AI models are increasingly being outperformed by, or failing to improve upon, traditional statistical methods and established clinical formulas in critical predictive tasks.
Hiring a commercial AI to read breast cancer biopsies does not just introduce errors; it forces clinicians to choose which specific flavor of diagnostic failure they can tolerate.